相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle et al.
ADVANCES IN THERAPY (2022)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
Linong Ji et al.
DIABETES OBESITY & METABOLISM (2021)
Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
Hitoshi Ishii et al.
DIABETES THERAPY (2021)
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial
Clare A. Whicher et al.
DIABETES OBESITY & METABOLISM (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M. S. Capehorn et al.
DIABETES & METABOLISM (2020)
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Tina K. Thethi et al.
DIABETES OBESITY & METABOLISM (2020)
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe et al.
Lancet Diabetes & Endocrinology (2020)
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada et al.
Lancet Diabetes & Endocrinology (2020)
Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials
Kah Kheng Goh et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2019)
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Dan Siskind et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
Johan Jendle et al.
DIABETES OBESITY & METABOLISM (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
Thomas R. Pieber et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia
Wade Marteene et al.
EXPERT OPINION ON DRUG SAFETY (2019)
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Ildiko Lingvay et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX)
Dan J. Siskind et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
Pelle L. Ishoy et al.
DIABETES OBESITY & METABOLISM (2017)
An Overview of Factors Associated with Adherence to Lifestyle Modification Programs for Weight Management in Adults
AliceW. Y. Leung et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2017)
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder A Randomized Clinical Trial
Julie R. Larsen et al.
JAMA PSYCHIATRY (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Attending to physical health in mental health services in Australia: a qualitative study of service users' experiences and expectations
Sarah J. Young et al.
HEALTH & SOCIAL CARE IN THE COMMUNITY (2017)
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Stephen J. Cooper et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular pathophysiology of metabolic effects of antipsychotic medications
Jacob S. Ballon et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2014)
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
Christoph U. Correll et al.
JAMA PSYCHIATRY (2014)
Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
L. Fredrik Jarskog et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Body mass index, waist circumference and quality of life in individuals with schizophrenia
Guy Faulkner et al.
SCHIZOPHRENIA RESEARCH (2007)
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Henry A. Nasrallah et al.
SCHIZOPHRENIA RESEARCH (2006)
Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness
Julie Kreyenbuhl et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2006)
Disparities in diabetes care - Impact of mental illness
SM Frayne et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Compliance with antipsychotic treatment
M Oehl et al.
ACTA PSYCHIATRICA SCANDINAVICA (2000)
分享论文
